Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alligator Bioscience ABOSTO:ATORX -3.60%39 PS Ratio is 24.46 as of Jul. 14, 2026, which is 23% below its 10-year median of 31.58. GuruFocus rates OSTO:ATORX with a GF Score™ of 39/100 and a GF Value™ of kr0.01 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 930 Biotechnology companies, Alligator Bioscience AB ranks worse than 69.14% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Alligator Bioscience AB's share price is kr0.1712.
Alligator Bioscience AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was kr0.01. Hence, Alligator Bioscience AB's PS Ratio for today is 24.46.
The historical rank and industry rank for Alligator Bioscience AB's PS Ratio or its related term are showing as below:
OSTO:ATORX'
s PS Ratio Range Over the Past 10 Years
Min: 0.01 Med: 31.58 Max: 174.36
Current: 24.46
During the past 12 years, Alligator Bioscience AB's highest PS Ratio was 174.36. The lowest was 0.01. And the median was 31.58.
OSTO:ATORX's PS Ratio is ranked worse than 69.14% of 930
companies
in the Biotechnology industry
Industry Median: 9.405
vs OSTO:ATORX: 24.46
Alligator Bioscience AB revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Alligator Bioscience AB was -100.00% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -85.80% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -49.70% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -39.30% per year.
During the past 12 years, Alligator Bioscience AB's highest 3-Year average Revenue per Share Growth Rate was 70.80% per year. The lowest was -85.80% per year. And the median was -39.60% per year.
Back to Basics: PS Ratio
Alligator Bioscience AB (OSTO:ATORX) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:ATORX vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's PS Ratio distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Alligator Bioscience AB's Share Price of today is kr0.1712. Alligator Bioscience AB's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Alligator Bioscience AB (OSTO:ATORX) has a PS Ratio of 24.46 as of Jul. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Alligator Bioscience AB and its competitors. This is 23% below median its historical median of 31.58. Over the past decade, Alligator Bioscience AB's PS Ratio has ranged from 0.01 to 174.36. According to the industry distribution chart, Alligator Bioscience AB ranks #643 out of 930 companies in the Biotechnology industry, placing it in the top 69.1%.
Is Alligator Bioscience AB's PS Ratio too high?
Alligator Bioscience AB's current PS Ratio of 24.46 is 23% below median its 10-year median of 31.58. Over the past 10 years, this metric has ranged from a low of 0.01 to a high of 174.36. The Biotechnology industry median PS Ratio is 9.41. Alligator Bioscience AB's value of 24.46 is 160.1% above this industry median. Based on the distribution chart, Alligator Bioscience AB ranks #643 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Alligator Bioscience AB has a GF Score™ of 39/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alligator Bioscience AB's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #643 out of 930 companies for PS Ratio. This places Alligator Bioscience AB in the lower half of its industry. The industry median PS Ratio is 9.41. Alligator Bioscience AB's value of 24.46 is 160.1% above this benchmark. Historically, Alligator Bioscience AB's own PS Ratio has ranged from 0.01 to 174.36 over the past decade. While the company's 10-year median is 31.58 vs. the industry median of 9.41, Alligator Bioscience AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.41, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alligator Bioscience AB's current PS Ratio of 24.46 is 160.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Alligator Bioscience AB and its competitors. For the Biotechnology industry, the median PS Ratio is 9.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alligator Bioscience AB's current PS Ratio is 24.46, which is 23% below median its own 10-year median of 31.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Based on GuruFocus' analysis, Alligator Bioscience AB (OSTO:ATORX) is currently considered Significantly Overvalued. The stock's GF Value™ is kr0.01, compared to a current price of kr0.17 — trading 1612% above its estimated fair value. The current PS Ratio is 24.46, which is 23% below median its 10-year median of 31.58 and 160.1% above the Biotechnology industry median of 9.41. Alligator Bioscience AB's overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Alligator Bioscience AB (OSTO:ATORX), the current PS Ratio is 24.46 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alligator Bioscience AB (OSTO:ATORX) Overvalued in 2026?
Based on GuruFocus' analysis, Alligator Bioscience AB stock appears to be overvalued.
The current stock price of kr0.17 is trading 1612% above its estimated GF Value™ of kr0.01.
GuruFocus considers Alligator Bioscience AB to be Significantly Overvalued.
Key valuation signals for OSTO:ATORX:
PS Ratio: 24.46 (23% below median its 10-year median of 31.58)
GF Value™: kr0.01 vs. price of kr0.17 (1612% above fair value)
Industry Position: 160.1% above the Biotechnology median (#643 of 930)
No single metric tells the full story. See the OSTO:ATORX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
39GF Score
Get the complete analysis for OSTO:ATORX
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ATORX has been successfully added to your 
